Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KN046 + Lenvatinib vs Docetaxel in Pre-treated Advanced NSCLC
NCT05001724Phase 3Terminated
- Sponsor
- Alphamab Oncology
- Start
- Oct 2021
- Primary completion
- Feb 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of erfonrilimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Alphamab Oncology. Primary endpoints: Dose Limiting Toxicity at 21 days, Overall Survival at 2 years and 1 more. Started Oct 2021; status: terminated.
02
Drugs
erfonrilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05001724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05001724.